Track market-moving stories before they get noisy

Expeditors International of Washington, Inc. (EXPD) Discusses Geopolitical Risks and Trade Tensions Impacting Europe, Russia, US, and China Transcript

NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Lucid Group, Inc. (“Lucid” or the “Company”) (NASDAQ: LCID) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 26-cv-05128, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lucid securities between February 25, 2026 and April 13, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired Lucid securities during the Class Period, you have until July 28, 2026, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

Lucid is a technology company that designs, develops, manufactures, and sells electric vehicles, EV powertrains, and battery systems. The Company’s products include, inter alia, the “Lucid Air” sedan and “Lucid Gravity” sport utility vehicle.

At all relevant times, Defendants touted purported enhancements to Lucid’s manufacturing and delivery capabilities and overall operations. In particular, beginning in late-February 2026, Defendants represented that, in fiscal year (“FY”) 2025, they had implemented sustainable improvements in these areas, including with respect to the production and ramp-up of deliveries of the Lucid Gravity. Defendants likewise asserted that these improvements would lead to profitable growth and performance efficiencies in FY 2026. Unbeknownst to investors, however, Lucid’s performance was materially hampered by significant supplier and delivery issues in February 2026, putting the Company on track for dismal, rather than improved, performance in its first quarter (“Q1”) of 2026.

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) a supplier quality issue had significantly disrupted deliveries of the Lucid Gravity; (ii) the foregoing was likely to, and did, have a material negative impact on the Company’s business and financial results; (iii) accordingly, the Defendants had overstated the purported enhancements to Lucid’s manufacturing and delivery capabilities and overall operations; and (iv) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

The truth began to emerge on April 3, 2026, when Lucid issued a press release “announc[ing its Q1 2026] production and delivery totals[.]” Lucid revealed that it had “produced 5,500 vehicles” during Q1 2026, while only “deliver[ing] 3,093 vehicles.” The press release further disclosed that, “[d]uring the quarter, deliveries of the Lucid Gravity were disrupted for 29 days due to a supplier quality issue with the second-row seats” and, “[a]s a result of this, the company’s ability to meet customer demand was impacted.”

The same day, Reuters published an article entitled “Lucid misses first-quarter vehicle delivery estimates on supplier disruptions”. The article provided additional color and comments from Defendant Marc Winterhoff (“Winterhoff”), the Company’s Interim Chief Executive Officer (“CEO”), regarding Lucid’s disappointing Q1 2026 delivery results—most notably that deliveries were particularly impacted over a month earlier in February 2026, when Lucid paused to reverse an unauthorized supplier change and inspect vehicles already produced.

The next trading day, April 6, 2026, 24/7 Wall St. published an article entitled “Lucid Faces Biggest Disaster Ever”, which described the number of vehicles that Lucid delivered in Q1 2026 as “remarkably small”, stating that Lucid “cannot sell fewer than 4,000 vehicles and even pretend this is sustainable.” 

Following the foregoing news and disclosures, Lucid’s stock price fell $1.13 per share, or 11.35%, over the following two trading sessions, to close at $8.83 per share on April 7, 2026.

On April 14, 2026, Lucid filed a current report on Form 8-K with the United States Securities and Exchange Commission (“U.S.”), reporting, inter alia, its preliminary Q1 2026 financial results, including revenue in the range of $280 million to $284 million—well below the consensus estimate of $433.8 million—and losses from operations in the range of $985 million to $1.005 billion.

The same day, Lucid issued a press release revealing its plans for a $1.05 billion capital raise, including a $300 million public stock offering.

Following these disclosures, Lucid’s stock price fell $0.44 per share, or 4.76%, to close at $8.80 per share on April 14, 2026.

Then, on May 5, 2026, Lucid issued a press release reporting its Q1 2026 financial results, including GAAP earnings per share of -$3.46, missing consensus estimates by $0.83, a net loss of over $1 billion, and revenue of $282.47 million, missing consensus estimates by $76.04 million. Defendant Winterhoff, as quoted in the press release, acknowledged that the previously disclosed “supplier issue . . . during the quarter had an impact,” and the need to “align[] production and delivery with customer demand.” Lucid’s Chief Financial Officer, Defendant Taoufiq Boussaid, as quoted in the same press release, likewise acknowledged that “[w]e ended the quarter with elevated inventory that we expect to convert to revenue and cash as deliveries normalize[.]”

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

In the latest close session, Lucid Group (LCID - Free Report) was down 4.38% at $5.02. This change lagged the S&P 500's 0.57% loss on the day. Meanwhile, the Dow experienced a rise of 0.64%, and the technology-dominated Nasdaq saw a decrease of 1.15%.

Shares of the an electric vehicle automaker witnessed a loss of 8.38% over the previous month, trailing the performance of the Auto-Tires-Trucks sector with its loss of 0.94%, and the S&P 500's gain of 2.14%.

The upcoming earnings release of Lucid Group will be of great interest to investors. On that day, Lucid Group is projected to report earnings of -$2.54 per share, which would represent year-over-year growth of 9.29%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $373.56 million, up 43.99% from the year-ago period.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$10.75 per share and revenue of $2.18 billion, indicating changes of +11.08% and +60.83%, respectively, compared to the previous year.

It is also important to note the recent changes to analyst estimates for Lucid Group. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Lucid Group is currently a Zacks Rank #4 (Sell).

The Automotive - Domestic industry is part of the Auto-Tires-Trucks sector. Currently, this industry holds a Zacks Industry Rank of 170, positioning it in the bottom 31% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Issued on behalf of Conexeu Sciences Inc.

A clutch of new directors with Fortune 500 finance, M&A, and aesthetics pedigrees signals that the newly public tissue-regeneration company is building for commercialization — in one of medicine's most consequential frontiers.

, /PRNewswire/ -- American News Group News Commentary — There is a well-worn pattern in the life sciences: a company spends years on the science, goes public, and then — in the critical window right after listing — races to assemble the kind of leadership bench that can turn a promising platform into a real business. The names a young company recruits in that window say a great deal about its ambitions. On June 15, 2026, Conexeu Sciences Inc. (Nasdaq: CNXU), a preclinical-stage regenerative-tissue company that began trading only weeks earlier, offered a revealing answer: it expanded its board from six to nine directors, promoted a co-founder to Chief Commercial Officer, and added a prominent aesthetics-industry figure to its advisory board — five appointments in all, weighted heavily toward Fortune 500 finance, capital-markets, and commercialization experience.

The move is less about any single hire than about what the collective résumé signals. For a company whose lead technology is still preclinical, building a board stocked with big-company financial and operating discipline is a statement of intent: that Conexeu means to be judged not as a science project, but as a company on a path to commercialization in one of the most consequential frontiers in medicine — helping the body regenerate its own tissue. Whether it can deliver on that intent remains years from resolution, but the governance build-out is the kind of step investors in early-stage medtech tend to watch closely.

Key Takeaways

Board expanded from six to nine: Conexeu appointed Ana Bastiani-Posner, April Burke, and Andrew Costa as new directors, deepening its bench across healthcare finance, capital markets, M&A, and growth equity. A commercialization signal: Co-founder and director David Bogart was named Chief Commercial Officer to lead commercial strategy and operations, having helped shape the company's platform and regulatory pathway from inception. An aesthetics heavyweight on advisory: Melinda Farina, known as "The Beauty Broker" and founder of Integrated Aesthetics Consulting and Beauty Brokers Inc., joined the advisory board, reinforcing Conexeu's push into the aesthetics market. Pedigree that stands out: The new directors bring senior roles from Kyowa Kirin, Allergan, Novartis, Schering-Plough, Lucid Hearing, RX3 Growth Partners (the consumer growth-equity firm co-founded by NFL quarterback Aaron Rodgers), Morgan Stanley, and J.P. Morgan. Context — momentum and risk: The appointments follow Conexeu's May 2026 Nasdaq listing and June bell-ringing, as it advances its preclinical CXU™ platform toward a targeted early-2027 FDA 510(k) submission — a milestone, not a guarantee. Who Conexeu Just Brought In

The headline additions are notable for their financial and operating heft. Ana Bastiani-Posner, named chair of the Compensation Committee and a member of the Audit Committee, is a C-suite executive with more than two decades of leadership across Fortune 500 companies; she currently serves as Executive Vice President and Chief Financial Officer of Kyowa Kirin North America, where she helps oversee roughly $1.2 billion in annual revenue, and has held senior roles at Allergan, the New York Genome Center, Schering-Plough, and Novartis. April Burke, joining the Audit and Compensation Committees, is Executive Vice President and CFO of Lucid Hearing, with expertise spanning public companies, private-equity-backed organizations, capital allocation, M&A, and IPO readiness.

Andrew Costa, named chair of the Audit Committee, rounds out the new directors as an investor and growth-equity operator with fifteen years across private equity, investment banking, and military leadership. He is Co-Managing Partner of RX3 Growth Partners — the consumer-focused growth-equity firm co-founded by NFL quarterback Aaron Rodgers, investing in health, wellness, and active-lifestyle brands, where he sits on boards including Therabody — and previously held investment-banking roles at Morgan Stanley and J.P. Morgan, after serving as a Captain in the U.S. Air Force. Alongside the board additions, co-founder and director David Bogart was elevated to Chief Commercial Officer; a capital-markets and investor-relations strategist who has advised on more than $75 million in capital formation, Bogart has helped shape Conexeu's IP and regulatory strategy since inception. And on the advisory side, Melinda Farina — "The Beauty Broker," with nearly three decades in medical aesthetics — brings consumer-health, brand-development, and market-positioning expertise directly relevant to Conexeu's aesthetics ambitions.

"Conexeu is entering an exciting new phase of growth, and it is important that our leadership team reflects the breadth of expertise needed to support both our scientific vision and business strategy," said Miles Harrison, CEO and President of Conexeu Sciences, adding that he looked forward to working with Bogart to "build our commercial foundation, expand our pipeline, and position Conexeu for scalable growth."

What the Company Is Actually Building

The leadership news only matters because of what sits beneath it. Conexeu is a preclinical-stage regenerative-tissue company built around a proprietary bioregenerative extracellular matrix platform it calls CXU™. The extracellular matrix is the natural scaffolding that surrounds cells in the body, providing the structural and biochemical cues that tell cells where to go and how to rebuild. Conexeu's lead device candidate, Ten-Minute Tissue™, is a thermosensitive ECM engineered to remain fluid at room temperature and then transition into a stable gel scaffold in place, at body temperature, within roughly ten minutes — a property designed to let it conform to and fill the irregular, three-dimensional geometry of real wounds and soft-tissue defects that flat sheets and powders struggle to address.

The company frames its strategy with a deliberately simple refrain — "one formula, one device" — a single platform engineered to scale across multiple billion-dollar markets rather than the traditional one-molecule, one-indication model. Those target markets include advanced wound care, periodontal applications, and facial and body contouring (including the soft-tissue laxity associated with rapid GLP-1-driven weight loss), with longer-term expansion into 3D printing and biofabrication and even veterinary medicine. Conexeu has also unveiled a 3D-bioprinted regenerative breast matrix program, branded B.R.E.A.S.T.™, in preclinical development with the Wake Forest Institute for Regenerative Medicine, aimed at moving breast reconstruction beyond implants toward true tissue regeneration. The platform rests on more than a decade of university preclinical research and is protected by issued patents across the U.S., E.U., Japan, and Australia, with Conexeu holding full rights and no royalty obligations. Management is pursuing a predicate-based U.S. regulatory route, with a 510(k) submission for its initial wound-care indication targeted for early 2027.

A Sector With Powerful Tailwinds — and Heavyweight Players

Conexeu is wading into a field with genuine momentum. The shift from simply replacing or covering damaged tissue toward actively regenerating it spans several large, growing markets — advanced wound care, medical aesthetics and body contouring, and surgical reconstruction — all propelled by aging populations, the diabetes epidemic, and, increasingly, the GLP-1 weight-loss wave and the soft-tissue changes that follow it. To understand both the scale of the opportunity and the competition, it helps to look at the established public companies operating across the markets Conexeu is targeting. They are far larger, commercial, and more diversified, which makes them useful reference points rather than direct equivalents.

Smith+Nephew plc (NYSE: SNN) is one of the clearest reference points for the wound-care and tissue-repair side of Conexeu's platform. A global medical-technology company explicitly focused on the repair, regeneration, and replacement of soft and hard tissue, Smith+Nephew operates a leading advanced wound management business and bioinductive regenerative implants. It illustrates the scale and breadth a tissue-technology franchise can reach — and the entrenched, well-capitalized competition any newcomer in regenerative wound care must eventually reckon with.

AbbVie Inc. (NYSE: ABBV) anchors the aesthetics comparison through its Allergan Aesthetics division, the dominant force in medical aesthetics with a multibillion-dollar franchise spanning injectables and body contouring. AbbVie has been actively addressing the aesthetic consequences of GLP-1-driven weight loss — precisely the soft-tissue laxity Conexeu is targeting — making it a powerful illustration of how large the aesthetics opportunity is, and how formidable the incumbent is in the market Conexeu hopes to enter with a regenerative approach.

Establishment Labs Holdings Inc. (Nasdaq: ESTA) is perhaps the most thematically precise comparison for Conexeu's breast program. A pure-play breast-aesthetics-and-reconstruction company built around its Motiva implants and tissue-expander technologies, Establishment Labs has grown into a company with more than $200 million in annual revenue. As Conexeu advances its B.R.E.A.S.T.™ bioprinted matrix toward a regenerative alternative to implant-based reconstruction, Establishment Labs represents both the established approach Conexeu aims to leapfrog and the commercial scale a focused breast-health franchise can achieve.

Stryker Corporation (NYSE: SYK) rounds out the group as one of the largest and most respected medical-technology companies in the world, with a substantial presence in wound care, regenerative and reconstructive products, and surgical solutions. Stryker exemplifies the diversified, large-cap medtech model and the commercialization machinery — sales, regulatory, and distribution muscle — that turns medical innovation into durable revenue. It is the kind of established player whose scale a platform company like Conexeu would aspire to over the long term. These companies are referenced to illustrate the sector and do not imply any partnership, endorsement, affiliation, or comparable financial performance; they are vastly larger, commercial-stage, and more diversified than Conexeu, which is an early-stage, preclinical company.

The Risks Behind the Promise

It is essential to keep Conexeu's stage of development front and center. This is a preclinical-stage company; its CXU™ platform is an investigational device candidate whose safety and effectiveness have not been established and which has not been reviewed or cleared by the FDA. The company's own disclosures caution that preclinical findings from laboratory and animal models may not predict human results, that its planned early-2027 510(k) submission may slip or face additional FDA data requests, and that marketing clearance may be delayed, limited, or never granted. A strong board does not change the fundamental reality that the science must still be proven in the regulatory arena.

There are commercial and financial risks as well. As a newly public, development-stage company in a capital-intensive field, Conexeu will need continued access to financing to fund the long road from preclinical work through manufacturing, regulatory testing, and commercialization — a path most product candidates never complete. It faces enormous, well-funded competition from the very kinds of companies referenced above, and the predicate-based 510(k) route, while potentially faster, does not remove the inherent uncertainty of medical-device development. Investors should weigh the genuine credibility a strengthened board lends against the substantial execution risk that remains.

Why It Still Matters

For all those caveats, the logic behind Conexeu's leadership build-out is sound, and the trajectory of its field is unmistakable. Regenerative medicine is moving from a scientific aspiration toward a commercial reality, propelled by demographic and metabolic trends that are only intensifying — an aging world, a diabetes epidemic, a GLP-1 boom reshaping the aesthetics landscape, and a broad shift from replacing tissue toward rebuilding it. Bringing in directors and executives who have operated at the scale of Kyowa Kirin, Allergan, Novartis, and the major investment banks is precisely how an early-stage company signals it intends to compete in that future rather than merely research it.

Whether Conexeu converts that intent into cleared products and durable revenue will be decided over years, in manufacturing suites and regulatory reviews, not in board announcements. But the company is assembling the pieces — a differentiated platform, a multi-market strategy, and now a leadership team built for commercialization — to pursue one of the most compelling questions in modern medicine: not how to replace what the body has lost, but how to help it rebuild. For investors tracking where regenerative medicine is headed, Conexeu's post-listing moves are a small but telling marker of a company positioning itself for the long game.

CONTINUED … Learn more about Conexeu Sciences Inc. at: https://www.conexeu.com

SEE WHAT THE MARKET IS TALKING ABOUT BEFORE IT MOVES

Eagle Eye reads social, forum, and news chatter across thousands of investor conversations in real time — and surfaces the tickers the crowd is piling into, along with the sentiment and catalysts behind them.

Explore Eagle Eye free (for now) at https://Eagle-Eye.dev

CONTACT:

American News Group

[email protected]

SOURCES:

[1] Conexeu Sciences Inc. — "Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing" (June 15, 2026; primary source for the board expansion, appointee bios, committee assignments, CXU™/Ten-Minute Tissue™ platform, and CEO Miles Harrison quote):

https://www.conexeu.com/resources/conexeu-expands-board-executive-and-advisory-leadership-with-five-appointments-post-nasdaq-listing

[2] Conexeu Sciences Inc. — "Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol 'CNXU'" (May 21, 2026; Nasdaq listing, platform overview):

https://www.conexeu.com/resources/conexeu-sciences-commences-trading-on-nasdaq-under-ticker-symbol-cnxu

[3] Conexeu Sciences Inc. — "Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program" (June 8, 2026; Q1 2027 510(k) plan, CDMO transfer, Ten-Minute Tissue™):

https://www.conexeu.com/resources/conexeu-sciences-reports-manufacturing-scale-up-and-regulatory-progress-for-lead-cxu-tm-wound-care-program

[4] Conexeu Sciences Inc. — "Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine" (May 27, 2026):

https://www.conexeu.com/resources/conexeu-sciences-initiates-preclinical-development-program-for-b-r-e-a-s-t-tm-bioregenerative-matrix-platform-with-wake-forest-institute-for-regenerative-medicine

[5] Establishment Labs Holdings Inc. — FY2025 results and company profile (NASDAQ: ESTA; breast aesthetics & reconstruction, Motiva, ~$211M 2025 revenue; sector/peer context with SNN, ABBV, SYK):

https://stockanalysis.com/stocks/esta/

DISCLAIMER:

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a digital media distribution and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.

American News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed by American News Group on behalf of MIQ. MIQ has been paid a fee for Conexeu Sciences Inc. advertising and digital media from Creative Direct Marketing Group ("CDMG"). This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article or email as the basis for any investment decision. MIQ does not own shares of Conexeu Sciences Inc. but reserves the right to buy and sell shares of Conexeu Sciences Inc. at any time without any further notice. There may be 3rd parties who may have shares of Conexeu Sciences Inc., and may liquidate their shares which could have a negative effect on the price of the stock. We also expect further compensation as an ongoing digital media effort to increase visibility for the company; no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been reviewed and approved on behalf of Conexeu Sciences Inc. by CDMG; this is a digital media distribution.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our publication is not trustworthy unless verified by their own independent research. Comparisons to other companies referenced in this publication are for contextual and illustrative purposes only and do not imply any partnership, endorsement, affiliation, or comparable financial performance. Forward-looking statements regarding leadership, preclinical and clinical development, manufacturing, regulatory submissions and clearances (including the planned first-quarter 2027 510(k) submission), reimbursement, market size, and commercialization are subject to risks and uncertainties, and actual results may differ materially. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

DraftKings (DKNG - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Over the past month, shares of this company have returned +11.7%, compared to the Zacks S&P 500 composite's +2.1% change. During this period, the Zacks Gaming industry, which DraftKings falls in, has gained 3.9%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, DraftKings is expected to post earnings of $0.34 per share, indicating a change of -10.5% from the year-ago quarter. The Zacks Consensus Estimate has changed -7.3% over the last 30 days.

For the current fiscal year, the consensus earnings estimate of $1.15 points to a change of +74.2% from the prior year. Over the last 30 days, this estimate has changed -2.8%.

For the next fiscal year, the consensus earnings estimate of $1.78 indicates a change of +54.4% from what DraftKings is expected to report a year ago. Over the past month, the estimate has changed -1.1%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for DraftKings.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For DraftKings, the consensus sales estimate for the current quarter of $1.57 billion indicates a year-over-year change of +3.9%. For the current and next fiscal years, $6.8 billion and $7.77 billion estimates indicate +12.4% and +14.2% changes, respectively.

Last Reported Results and Surprise HistoryDraftKings reported revenues of $1.65 billion in the last reported quarter, representing a year-over-year change of +16.8%. EPS of $0.2 for the same period compares with $0.12 a year ago.

Compared to the Zacks Consensus Estimate of $1.64 billion, the reported revenues represent a surprise of +0.12%. The EPS surprise was -9.09%.

Over the last four quarters, DraftKings surpassed consensus EPS estimates times. The company topped consensus revenue estimates two times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

DraftKings is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about DraftKings. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Dave & Buster's Entertainment (NASDAQ:PLAY) reported a steeper-than-expected drop in first-quarter profit and revenue as softer consumer sentiment and a marketing misstep weighed on comparable store sales.

The video game and restaurant chain posted adjusted earnings per share of $0.22 for the quarter, falling well short of the analyst consensus of approximately $0.90.

Revenue declined 1.5% year-over-year to $559.2 million, missing the $580.6 million expected by analysts.

Comparable store sales fell 5.4% in the quarter, significantly worse than the consensus estimate of a 1.2% decline. The company attributed the shortfall to macroeconomic headwinds including elevated gas prices and geopolitical uncertainty, as well as promotional tests that failed to connect with cost-conscious consumers.

Despite the weak headline results, management pointed to early signs of stabilization. Quarter-to-date comparable sales through mid-June were running at negative 4%, and the company said it expects to return to positive comparable sales for the remainder of fiscal 2026, beginning in mid-June, driven by a new games lineup, World Cup activations and a revitalized loyalty program with personalized offers.

The company also cited momentum in its food and beverage segment, where comparable sales rose 5% year-over-year for the ninth consecutive month of positive growth, and in special events, which saw a 3% comparable sales gain.

On the operational side, Dave & Buster's reported a meaningful swing in adjusted free cash flow, improving to positive $25.3 million from negative $58.8 million in the prior year period. Management reiterated its fiscal 2026 target of generating more than $100 million in free cash flow, with approximately $499 million in total liquidity.

Dave & Buster's also reported continued international expansion, opening its fifth and sixth franchise locations in May and June 2026, including a partnership to develop 15 venues in India.

Jefferies analysts said they view risk/reward as skewed to the upside at current valuations.

The firm noted the stock trades at roughly 4 times estimated 2027 EBITDA, a discount to most full-service peers at 5 to 12 times.

The bank lowered its 2026 comparable sales estimate to negative 2.4% and cut its adjusted EBITDA forecasts for 2026 and 2027 to $433 million and $469 million, respectively.

Shares opened about 2.6% lower on Tuesday.

Dave & Buster’s stock is among today’s weakest performers. What’s pressuring PLAY stock? Earnings HighlightsDave & Buster’s reported adjusted earnings per share of 22 cents, missing the consensus estimate of 61 cents. In addition, it reported revenue of $559.20 million, missing the consensus estimate of $580.46 million and representing a 1.5% year-over-year decline.

Comparable store sales fell 5.4% compared to the same period in fiscal 2025. The company ended the quarter with $499.1 million in available liquidity.

Dave & Buster’s opened one new domestic store in the first quarter and three additional domestic stores in the second quarter. The company has completed six store remodels in fiscal 2026 and expects two more by year-end. Its international franchise footprint expanded to six stores with openings in May and June.

“While first quarter results fell short of expectations, our back-to-basics strategy is gaining clear traction,” said Tarun Lal, CEO. “We are highly confident in our ability to drive positive comps for the remainder of the year while generating over $100 million in free cash flow in fiscal 2026.”

Analyst Consensus & Recent ActionsThe stock carries a Hold rating with an average price target of $14.67. Recent analyst moves include:

UBS: Neutral (Lowers Target to $12.00) (June 16) Dave & Buster’s Shares CraterPLAY Price Action: At the time of publication, Dave & Buster’s shares are trading 18.02% lower at $10.10, according to data from Benzinga Pro.

This illustration was generated using artificial intelligence via Midjourney.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

-

Includes all-new Marvel Infinity Comics series and access to expansive digital catalog of comics

New York, NY--(BUSINESS WIRE)--USA TODAY PLAY, a unified digital hub for casual entertainment and gaming, part of USA TODAY Co., Inc. (NYSE: TDAY), announced a collaboration with Marvel Comics to provide an exclusive vertically-formatted Marvel Infinity “Spider-Man TODAY” Comic series to USA TODAY PLAY. The all-new specially created comic “Spider-Man TODAY” weekly subscriber series written by Al Ewing and illustrated by Todd Nauck will publish every Wednesday for the next 47 weeks showcasing the adventures of the web-slinger teaming up with heroes from across the Marvel Universe.

Additionally, USA TODAY PLAY subscribers can enjoy unlimited access to a catalog of 1,000 digital comics from Marvel’s expansive breadth of characters and storylines including X-Men, Captain America, Black Panther, Fantastic Four, Guardians of the Galaxy, and Captain Marvel among many others. *Non-subscribers can explore a curated weekly selection.

“We’re thrilled to expand the USA TODAY PLAY brand through this exciting collaboration with Marvel,” said Dara Sanderson, Vice President and General Manager of USA TODAY PLAY. “We’re continuing to broaden our offerings, and this project is a testament to that. By blending iconic storytelling with interactive experiences true to the USA TODAY PLAY ethos, we continue to create daily moments that provide users well-deserved breaks from everyday stressors.”

“As digital comics continue to grow, we have the opportunity at Marvel to bring our comics to more fans across different platforms,” said Jon-Michael Ennis, Director of Digital Publishing at Marvel. “We’re excited to be working with USA TODAY to invite even more people to experience our comic book storytelling, whether they’re brand new to comics or lifelong readers.”

Featuring digital comics, puzzles, games and more, USA TODAY offers multiple ways to PLAY. Users can access content ad-free with a subscription, or for free using an ad-supported option. Paid subscribers also enjoy additional benefits, including unlimited hints and reveals in puzzles, full access to archival content, and early access to select new features.

*Subscription Pricing and Availability (subject to applicable terms and conditions)

USA TODAY PLAY monthly subscription: $0.99 for the first month, then $4.99 per month USA TODAY PLAY annual subscription: $39.99 per year Add USA TODAY PLAY monthly subscription to an existing USA TODAY Network subscription: $2 per month Add USA TODAY PLAY annual subscription to an existing USA TODAY Network subscription: $24 per year Anonymous Users: Enjoy access to 1 free Marvel comic a week (from a curated selection of 10) Registered Users: Enjoy access to 2 free Marvel comics a week (from a curated selection of 10) ABOUT USA TODAY CO., INC.

USA TODAY Co., Inc. is a diversified media company with expansive reach at the national and local level dedicated to empowering and enriching communities. Our mission is to inspire, inform, and connect audiences. As a media and digital marketing solutions company we are focused on sustainable growth. Through our trusted brands, including the USA TODAY NETWORK, comprised of the national publication, USA TODAY, and our network of local properties, in the United States, and Newsquest, a wholly-owned subsidiary operating in the United Kingdom, we provide essential journalism, local content, and digital experiences to audiences and businesses. We deliver trusted unbiased journalism when and where consumers want it. LocaliQ, our digital marketing solutions brand, supports small and medium-sized businesses with innovative digital marketing products and solutions.

ABOUT USA TODAY

Since its introduction in 1982, USA TODAY has been a cornerstone of the national media landscape under its recognizable and respected brand. It also serves as the foundation for our newsroom network which allows for content sharing capabilities across our local and national markets. Through USA TODAY, we deliver high-quality, trusted content with a commitment to balanced, unbiased journalism, where and when consumers want to engage. Across our digital platforms we reach an audience of approximately 87 million unique visitors each month (based on December 2025 Comscore Media Metrix®).

ABOUT MARVEL

Marvel is one of the world’s most prominent entertainment brands, built on an unparalleled library of iconic characters and stories that have shaped pop culture for over 85 years. The Marvel brand spans entertainment, including film, television, publishing, licensing, games, live events, digital media, and more. For more information visit marvel.com. © 2026 MARVEL

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that relate to our current expectations and views of future events. All statements other than statements of historical facts contained in this press release, including statements relating to whether this initiative will enable USA TODAY Co. to increase sales or revenues, beliefs, intentions, estimates or strategies regarding the future, which may not be realized. In some cases, you can identify forward-looking statements by terms such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” “could,” “will,” “would,” “ongoing,” “future” or the negative of these terms or other similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are based largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements involve known and unknown risks, uncertainties, contingencies, changes in circumstances that are difficult to predict and other important factors that may cause our actual results, performance, or achievements to be materially and/or significantly different from any future results, performance or achievements expressed or implied by the forward-looking statement. For a discussion of some of the risks and important factors that could cause actual results to differ materially from our expectations, see the risks and other factors detailed in “Item 3. Key Information - Risk Factors” in USA TODAY Co.’s (fka Gannett Co., Inc.) 2025 Annual Report on Form 10-K and USA TODAY Co.’s (fka Gannett Co., Inc.) quarterly reports on Form 10-Q and USA TODAY Co.’s (fka Gannett Co., Inc.) other filings with the SEC, in each case as such factors may be updated from time to time. Any forward-looking statements contained in this press release speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. USA TODAY Co. disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.

More News From USA TODAY Co., Inc.

Back to Newsroom

Dave and Buster's Entertainment Inc. (NASDAQ:PLAY) reported downbeat earnings for the first quarter after the closing bell on Monday.

The company posted quarterly earnings of 22 cents per share, which missed the analyst consensus estimate of 61 cents per share. The company reported quarterly sales of $559.200 million, which missed the analyst consensus estimate of $580.461 million.

Dave and Buster's shares fell 8.8% to trade at $11.23 on Tuesday.

These analysts made changes to their price targets on Dave and Buster's following earnings announcement.

UBS analyst Dennis Geiger maintained the stock with a Neutral and lowered the price target from $13 to $12. BMO Capital analyst Andrew Strelzik maintained the stock with an Outperform rating and lowered the price target from $24 to $22. Benchmark analyst Mike Hickey downgraded Dave & Buster’s from Buy to Hold. Considering buying PLAY stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Dave & Buster's PLAY is experiencing significant pressure after falling short of expectations in its Q1 (April) report. The company reported a notable EPS miss, with revenue declining 1.5% year-over-year to $559.2 million. The primary concern appears to be a drop in customer traffic, particularly during the peak spring break season in March and April, attributed to macroeconomic pressures and declining consumer sentiment. However, management pointed to improving free cash flow, positive trends in food and beverage sales, and strong performance from remodeled locations as indicators that internal changes are beginning to take effect.

Traffic and Food & Beverage Performance: Same-store sales fell by 5.4%, worsening from a 3.3% decline in Q4 (January). On a positive note, food and beverage comps increased by approximately 5%, marking nine consecutive months of growth in this area, indicating that the main issue lies with entertainment traffic. Challenges: The company's $1-per-day promotional messaging did not resonate as intended, compounded by macroeconomic pressures and weaker consumer sentiment during March and April. Although Q2-to-date comps have improved, they remain down about 4%. Successful Remodels: The remodeled locations have outperformed the overall system by nearly 700 basis points. Management noted that the new prototype remodels cost about half of the previous versions while delivering a 7% comp uplift. Traffic Recovery Initiatives: PLAY is working to boost traffic through a marketing reset, new promotions, fresh game offerings, World Cup activations, and value deals like Eat & Play bundles. The company recently introduced 10 new games and anticipates adding at least five more this year. Capital Allocation Strategy: PLAY plans to open 11 new stores in FY26 but has expressed a willingness to allocate more capital towards remodels and core business improvements. Future openings in FY27 and FY28 may slow to around five per year. Future Outlook: The company is still targeting positive comps for the remainder of FY26, along with EBITDA growth and over $100 million in free cash flow. Analysts note that this was not the anticipated start for PLAY or its investors as the company navigates its turnaround. Comp sales have declined in Q1, and while macroeconomic headwinds impacted the busy spring break season, the execution of the promotional strategy also fell short. Although improvements in food and beverage trends, successful remodels, and enhanced free cash flow indicate some internal progress, they have not sufficiently countered the decline in traffic and entertainment revenue. With Q2-to-date comps still down about 4%, it remains challenging to support management's goal for positive comps for the rest of FY26. Until PLAY demonstrates a recovery in traffic and entertainment revenue, investor skepticism regarding the turnaround may persist, despite the positive signs from remodels and cash flow.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Dave & Buster's Entertainment PLAY shares fell about 4% after the company reported weaker-than-expected fiscal first-quarter 2026 results, as softer customer demand and higher operating costs weighed on sales and profitability.

The restaurant and entertainment operator posted adjusted earnings per share of $0.22, missing analysts' consensus estimate of $0.37.

The figure also declined significantly from adjusted earnings of $0.76 per share reported in the year-ago quarter.

Revenue totaled $559.2 million, falling short of Wall Street expectations of approximately $571 million and declining 1.5% from the prior year.

The company said lower comparable-store sales contributed to the revenue decline, partially offset by growth from newer locations.

The quarter was marked by weaker traffic at existing locations, particularly within the company's higher-margin entertainment business.

Comparable-store sales, including Main Event-branded locations, declined 5.4% year over year.

Management attributed the decline largely to reduced walk-in traffic compared with the same period last year.

The weakness came despite continued efforts to improve customer engagement through promotional initiatives and operational enhancements.

Dave & Buster's Chief Executive Officer, Tarun Lal, said the company entered the quarter with positive momentum before broader economic conditions affected consumer behavior.

“Of the macro backdrop, elevated gas prices, geopolitical uncertainty and a meaningful softness in consumer sentiment. They all were a real headwind in April.”

The softer demand environment weighed on discretionary spending, affecting both customer visits and overall sales trends during the quarter.

Performance varied significantly across business segments.

Food and beverage revenue increased 6.5% year over year to $214.1 million, supported by menu updates and enhancements to the company's eat-and-play combo offerings introduced during the second half of fiscal 2025.

The company said these initiatives helped improve food attachment rates and average customer spending.

However, entertainment revenue declined 5.9% year over year to $345.1 million.

Since arcade and gaming operations typically generate higher margins than food and beverage sales, the shift in revenue mix created additional pressure on profitability.

Management also reviewed the effectiveness of its marketing efforts during the quarter.

“We found that our dollar per day messaging did not resonate as strongly as we hoped. And since then, we have pivoted to more compelling promotions, which are resonating with customers,” said Lal.

The company said it has since adjusted its promotional strategy in an effort to better connect with value-conscious consumers.

Profitability weakened during the quarter as lower sales leverage combined with higher expenses.

Operating income declined to $46.9 million from $63.2 million a year earlier. Operating margin fell to 8.4% from 11.1%.

Adjusted EBITDA totaled $123.2 million, down from $136.1 million in the prior-year quarter. Adjusted EBITDA margin contracted to 22% from 24%.

Despite the disappointing results, management highlighted progress in several areas of its turnaround strategy.

The company said improvements to food and beverage offerings, marketing initiatives, and its remodel program are helping enhance the guest experience.

Dave & Buster's also continued to invest in future growth through new store openings, remodel projects, and international franchise expansion.

Management indicated that these initiatives remain central to its long-term strategy despite near-term challenges from a cautious consumer environment.

Urges Stockholders to Vote “FOR” ALL Six of Vaxart’s Director Nominees on the WHITE Proxy Card TODAY

Visit Vote.Vaxart.com for Additional Information and Voting Resources

SOUTH SAN FRANCISCO, Calif., June 16, 2026 (GLOBE NEWSWIRE) --  Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today mailed a letter to shareholders from the Board’s two newest independent directors, James Breitmeyer, M.D., Ph.D., and Kevin Finney, urging them to vote “FOR” ALL six of the company’s highly qualified director nominees on the WHITE proxy card in connection with its upcoming Annual Meeting of Stockholders scheduled to be held on July 16, 2026.

The full text of the letter is as follows:

Dear Fellow Shareholders,

We are Vaxart’s two newest independent directors, having each joined the Board in the last 18 months. We’d like to take this opportunity to explain why we both believe your vote on the WHITE proxy card “FOR” ALL of Vaxart’s directors before the July 16th Annual Meeting is essential.

Between us, we have spent more than 70 years in biotechnology, with expertise spanning clinical development, regulatory strategy, financing, business development and executive leadership. We joined the Board with the explicit purpose of providing fresh perspectives and open minds. We did not come to this Boardroom with preconceived notions or established relationships with Vaxart’s other directors.

We view our roles as the newest members to critically evaluate and review the Company’s current strategy. We are leveraging our respective experiences and very high expectations to hold management accountable for the Company’s performance and execution of its strategy.

Our time on the Board has reinforced that this is a team committed to creating shareholder value. Vaxart is on the brink of unlocking the value of years of scientific innovation. But there is much more work that needs to be done. This is not the time to disrupt a Board that has the experience, independence and judgment to oversee the path forward.

We recommend that shareholders vote on the WHITE proxy card “FOR” ALL 6 of Vaxart’s directors.

Our Board is Driving Vaxart Forward and Holding Management Accountable

Since we joined Vaxart, it has been clear to us that this Board is active, informed and willing to change when needed. Each of the Board’s members brings important and relevant skills to the table and plays an active role in steering the Company to success. Our Board discussions are frequent and substantive. Management is pushed. Alternatives are considered. Decisions are evaluated through the lens of clinical progress, capital discipline, strategic opportunity and long-term shareholder value.

The directors at the center of this election – Steven Lo, Dr. Elaine J. Heron and Dr. David Wheadon – all bring experience that is directly relevant to Vaxart’s needs today: proven life sciences and drug development track records, public company and operational leadership, and decades of clinical research and regulatory experience. Those perspectives are not theoretical.

Removing these directors and replacing them with unqualified nominees would immediately undermine the Company’s ability to bring informed, experienced judgment to the decisions that matter most for Vaxart’s future and to advance critical government and commercial relationships that are essential to success.

Vaxart Leadership is Successfully Navigating a Difficult Macro and Industry Environment

Like many other companies in our industry, Vaxart has faced macro challenges beyond any individual company’s control, including the stop-work orders BARDA issued across many vaccine programs in early 2025. This Board responded decisively, working with management to secure funding for the ongoing Phase 2b COVID-19 study, strengthening Vaxart’s financial position through the Dynavax partnership, streamlining operations and extending the Company’s runway.

These were consequential actions taken to preserve Vaxart’s opportunity to operate. In our view, they demonstrate the kind of oversight and action Vaxart needs: engaged, pragmatic and made possible because of the specific experience and expertise our Board and management team bring to the table. Our CEO, Steven Lo, has been instrumental in all of these efforts. We fully endorse his leadership, and we believe that the actions he has taken have been essential to keeping the Company in business and on a path to realizing the value of our pipeline.

We have seen that same discipline and sense of purpose inside the Company. Recently, Jim spent time with members of Vaxart’s research and development organization. The conversations were candid, data-driven and grounded in a realistic understanding of Vaxart’s opportunities and challenges. The excitement is palpable and we are full steam ahead.

Vote the WHITE Proxy Card Today

Vaxart needs directors who understand the Company at every level and who can apply that knowledge to our future. The current Board brings that exact combination of relevant expertise, Company-specific context and accountability to shareholders. With important clinical and operational milestones ahead, continuity of experienced oversight matters. Focus matters. Avoiding unnecessary disruption matters.

A group of dissident shareholders is seeking to add themselves to the Board and replace half of Vaxart’s directors. These dissident nominees have claimed that Vaxart needs directors who bring stronger oversight and greater accountability. That is not our experience. And the dissident nominees are certainly not the people who will advance our programs, strengthen our partnerships or ensure Vaxart has the financial resources to achieve its goals in this environment.

We joined this Board because we believe in Vaxart’s mission and its potential. We are committed to taking the actions necessary and to holding management’s feet to the fire, so we can bring Vaxart’s important vaccines to market and create value for shareholders.

Join us in voting “FOR” ALL 6 of the Company’s highly qualified director nominees on the WHITE proxy card TODAY. Thank you for your continued support.

Sincerely,

James B. Breitmeyer, M.D., Ph.D., and Kevin P. Finney

Vote “FOR” ALL 6 of Vaxart’s highly qualified director nominees on the WHITE proxy card TODAY!

If you have questions or require assistance with voting your shares, please call Vaxart’s proxy solicitor:

Campaign Management, LLC
Toll-Free: +1 (855) 264-1527

Additional shareholder resources and voting information can be found at Vote.Vaxart.com.

About Vaxart

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Cautionary Language Concerning Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” provisions created by those sections, that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this communication regarding Vaxart’s strategy, prospects, plans and objectives, results from preclinical and clinical trials, commercialization agreements and licenses, and beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as “should,” “believe,” “could,” “potential,” “will,” “expected,” “anticipate,” “plan,” “target,” “seek,” “intend,” “may,” “predict,” “project,” “would,” and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart’s ability to develop and commercialize its product candidates, including its vaccine booster products; Vaxart’s expectations regarding clinical results and trial data, and the timing of receiving and reporting such clinical results and trial data; Vaxart’s expected timing for future clinical trials; and Vaxart’s expectations with respect to the effectiveness of its product candidates; expectations regarding collaborations, including the collaboration with Dynavax; expectations regarding the pursuit of strategic partnerships and external funding opportunities for Vaxart’s programs; expectations regarding government funding; and expectations regarding Vaxart’s capital resources and funded runway. Vaxart may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates, and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart’s product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart’s product candidates may not achieve broad market acceptance; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart’s or its partners’ control; difficulties in production, particularly in scaling up initial production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; that Vaxart may not be able to obtain, maintain, and enforce necessary patent and other intellectual property protection; that Vaxart’s capital resources may be inadequate; Vaxart’s ability to resolve pending legal matters; Vaxart’s ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks and uncertainties described in the “Risk Factors” sections of Vaxart’s most recent Annual Report on Form 10-K, including amendments thereto, and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. Vaxart undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Important Additional Information and Where to Find It

 Vaxart has filed a definitive proxy statement and form of white proxy card with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its solicitation of proxies for the 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Stockholders are able to obtain the Company’s proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC at no charge at the SEC’s website at www.sec.gov. Copies are also available at no charge at the Company’s website at https://investors.vaxart.com/financials-filings/sec-filings.

Investor Contact

Michael Fein
Campaign Management
(855) 264-1527

Media Contact

Aaron Palash / Adam Pollack
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

Part 1 of this article compares RITM's recent investment composition, leverage, hedging coverage ratio, quarterly BV, economic return (loss), and current valuation to 17 mREIT peers. Due to what has occurred during Q2 2026 (fluctuating rates/yields), understanding the composition of RITM's MSR/investment and derivatives portfolio is crucial in understanding current/future performance. My current RITM BV projection and updated price target is in the “Conclusions Drawn” section. RITM is currently deemed notably undervalued (strong buy recommendation).

In the latest close session, Sirius XM (SIRI - Free Report) was up +1.46% at $27.86. The stock outpaced the S&P 500's daily loss of 0.57%. On the other hand, the Dow registered a gain of 0.64%, and the technology-centric Nasdaq decreased by 1.15%.

Shares of the satellite radio company witnessed a gain of 5.25% over the previous month, beating the performance of the Consumer Discretionary sector with its gain of 2.7%, and the S&P 500's gain of 2.14%.

Investors will be eagerly watching for the performance of Sirius XM in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $0.78, reflecting a 36.84% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.14 billion, up 0.11% from the year-ago period.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $3.1 per share and a revenue of $8.56 billion, indicating changes of -2.82% and +0.02%, respectively, from the former year.

Investors should also note any recent changes to analyst estimates for Sirius XM. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Sirius XM is currently a Zacks Rank #3 (Hold).

Investors should also note Sirius XM's current valuation metrics, including its Forward P/E ratio of 8.85. This valuation marks a discount compared to its industry average Forward P/E of 12.69.

It is also worth noting that SIRI currently has a PEG ratio of 0.59. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Broadcast Radio and Television was holding an average PEG ratio of 1.04 at yesterday's closing price.

The Broadcast Radio and Television industry is part of the Consumer Discretionary sector. This industry, currently bearing a Zacks Industry Rank of 109, finds itself in the top 45% echelons of all 250+ industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Published June 16, 2026 4:21pm EDT

The layoffs took effect Tuesday and follow multiple rounds of job cuts over the past year Elective vehicle-maker Rivian is laying off hundreds of workers in its service and customer organization.

A company spokesperson told FOX Business that the job cuts represent less than 2% of Rivian's workforce, which totaled about 15,200 employees at the end of 2025. Workers affected by the layoffs may apply for other open roles at the company.

"We recently restructured a handful of teams within Rivian as we work to profitably scale our business," the spokesperson said.

AUTOMAKER GEARS UP FOR SELF-DRIVING FUTURE WITH NEW CHIP

Rivian began releasing R2 SUVs last week, which are a key part of its product roadmap. (Scott Olson/Getty Images)

The job cuts took effect on Tuesday and affected Rivian's service and customer division, which is responsible for sales and marketing duties, as the company looks to restructure its teams to grow efficiently while rolling out a new model.

The Wall Street Journal first reported the layoffs.

Rivian recently conducted multiple rounds of layoffs in the last year while it prepared for the launch of the R2 SUV, which factors heavily into the EV-maker's roadmap for future products.

RIVIAN CEO DISCUSSES TARIFFS, SAYS EV MAKER HAS 'VERY US-CENTRIC SUPPLY CHAIN'

Ticker Security Last Change Change % RIVN RIVIAN AUTOMOTIVE INC. 15.93 -0.75 -4.50% It cut over 600 jobs, or 4.5% of its workforce, in October amid softer demand for its vehicles following the expiration of EV tax credits in October.

The R2 officially debuted last week with a variant that had a larger number of optional add-ons for a starting price around $58,000 – while the automaker is planning to release more affordable versions in the future.

RIVIAN TO LAY OFF 10% OF SALARIED STAFF

Rivian also conducted layoffs last year following the expiration of EV tax credits. (Reuters/Kevin Krolicki/File Photo)

The company is hoping that the lower-cost model will broaden demand and strengthen its sales outlook as it strives for profitability.

Rivian has said that it no longer expects to meet its 2027 adjusted core profit target as it ramps up spending on research and development to accelerate its autonomous driving roadmap.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Reuters contributed to this report.

NEW YORK--(BUSINESS WIRE)--JetBlue (NASDAQ: JBLU) today announced the next evolution of its award-winning Mint® experience with the introduction of Kent Hospitality Group and its strategic partner, Four Clovers Hospitality Group, as JetBlue's new onboard culinary partners. The collaboration brings a fresh, sophisticated and distinctly New York approach to inflight dining, elevating JetBlue's premium business class experience with the creative forces behind some of the city's most coveted restau.

Key Takeaways Lam Research expects advanced packaging revenues to grow more than 50% in 2026.AI chips need advanced packaging to boost performance, bandwidth and power efficiency.Lam Research's Q3'26 revenues rose 24% year over year to a record $5.84 billion. Lam Research Corporation’s (LRCX - Free Report) advanced packaging business is emerging as an important growth driver. With artificial intelligence (AI) driving major changes in chip design, this business could become a meaningful catalyst for future growth.

Unlike traditional semiconductor manufacturing, AI chips require advanced packaging techniques to connect multiple processors and memory components in a compact structure. This improves performance, bandwidth and power efficiency. As a result, chipmakers are increasing investments in packaging technologies, creating additional demand for Lam Research’s etch and deposition equipment.

The company expects advanced packaging revenues to grow more than 50% in 2026, far outpacing many other semiconductor equipment categories. Lam Research is benefiting from rising adoption of high-bandwidth memory (HBM), AI accelerators and chiplet-based architectures, all of which depend heavily on advanced packaging processes.

The company’s overall business remains strong. In the fiscal third quarter of 2026, revenues increased 24% year over year to a record $5.84 billion, while non-GAAP gross margin expanded 90 basis points to 49.9%. Systems revenues climbed 24% to $3.73 billion, reflecting healthy demand across memory and foundry customers. Customer Support Business Group revenues also rose 25% to a record $2.11 billion, providing recurring revenue support.

The long-term opportunity for advanced packaging may be even larger. As AI models become more powerful, semiconductor companies are expected to rely increasingly on advanced packaging to overcome the limits of traditional chip scaling. This shift could expand Lam Research’s served market beyond conventional wafer processing. If the company executes well in this market, packaging could evolve from a niche business into a meaningful contributor to future revenue and earnings growth.

LRCX’s Rivals Are Also Targeting Packaging GrowthTwo major Lam Research competitors, Applied Materials, Inc. (AMAT - Free Report) and KLA Corporation (KLAC - Free Report) , are also benefiting from the advanced packaging boom. Both companies are expanding their presence in technologies that support AI chips, high-bandwidth memory and chiplet-based architectures.

Applied Materials is perhaps the closest competitor to Lam Research in advanced packaging. The company has highlighted advanced packaging as a multibillion-dollar opportunity and continues to develop materials engineering solutions for 2.5D and 3D chip integration. In the last reported results for the second quarter of fiscal 2026, Applied Materials’ revenues increased 11% to $7.91 billion, with its Semiconductor Systems segment remaining the primary growth engine. Rising investments in AI accelerators and HBM are expected to drive further demand for its packaging-related tools.

KLA participates in the market through process control, inspection and metrology solutions. As advanced packages become more complex, chipmakers require additional inspection steps to improve yields and reduce defects. KLA’s second-quarter fiscal 2026 revenues increased 11.5% year over year to $3.42 billion. The company continues to benefit from growing demand for advanced packaging process control technologies. KLAC expects its semiconductor process control advanced packaging portfolio revenues to grow from about $635 million in 2025 to about $1 billion in 2026.

For Lam Research, the opportunity is significant, but competition is intense. Continued innovation in etch and deposition technologies will be critical if the company wants to capture a larger share of the rapidly expanding advanced packaging market.

LRCX’s Share Price Performance, Valuation and EstimatesShares of Lam Research have surged 127.2% year to date compared with the Zacks Electronics – Semiconductors industry’s rise of 52.5%.

Lam Research YTD Price Return Performance
Image Source: Zacks Investment Research

From a valuation standpoint, Lam Research trades at a forward price-to-earnings ratio of 50.78, significantly higher than the industry’s average of 35.02.

Lam Research Forward 12-Month P/E Ratio
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Lam Research’s fiscal 2026 and 2027 earnings implies a year-over-year increase of approximately 37.7% and 35.8%, respectively. Estimates for fiscal 2026 have been revised upward over the past seven days, while estimates for fiscal 2027 have been raised northward over the past 30 days.

Image Source: Zacks Investment Research

Lam Research currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

On June 16, 2026, we present a discounted cash flow (DCF) analysis for CSX Corp CSX . The company has shown notable price performance, with a year-to-date increase of 31.6% and a one-year gain of 49.6%. Below are key points from our analysis:

DCF Earnings-based intrinsic value of $30.68 vs current price of $47.39 (margin of safety: -54.5%) DCF FCF-based intrinsic value of $26.64 vs current price (second opinion) GF Score™ of 86/100 indicating high reliability of the DCF inputs What Is CSX Worth? DCF Earnings-Based Model The DCF earnings-based model evaluates CSX's intrinsic value based on its projected earnings growth over the next decade. The model operates in two stages: a growth phase followed by a terminal phase. Below are the assumptions used in the calculation:

Parameter Value Current EPS (TTM, excl. non-recurring) $1.70 10-Year Growth Rate 11.8% 10-Year Treasury Rate 4.44% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% In the first stage, we project that CSX's EPS will grow at an annual rate of 11.8% for the next 10 years, discounted at a rate of 11%. The value derived from this growth phase is $17.69 per share. In the second stage, we assume a terminal growth rate of 4% for the subsequent 10 years, also discounted at 11%, yielding a terminal value of $12.99 per share. The summary of the calculations is as follows:

Stage Description Value Growth Stage (Years 1-10) EPS growing at 11.8%, discounted at 11% $17.69 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $12.99 Intrinsic Value Growth + Terminal $30.68 With the current price of CSX at $47.39, the intrinsic value of $30.68 indicates that the stock is modestly overvalued, with a margin of safety of -54.5%. It is important to note that GuruFocus uses EPS excluding non-recurring items, as research shows that stock prices correlate more closely with earnings than free cash flow. For further details, you can visit the CSX DCF Calculator.

What Does the Free Cash Flow DCF Say? The free cash flow (FCF)-based intrinsic value for CSX is calculated at $26.64. When comparing this to the earnings-based intrinsic value of $30.68, both models suggest that CSX is modestly overvalued, with a margin of safety of -77.9%. This significant difference in intrinsic values highlights the importance of considering multiple valuation methods.

How Does GF Value™ Compare to the DCF Models? The GF Value™ for CSX is calculated at $35.44, providing a third perspective on the company's valuation. GF Value™ is GuruFocus' proprietary measure derived from historical trading multiples, past business growth, and future performance estimates. All three models—DCF earnings, DCF FCF, and GF Value™—indicate that CSX is overvalued at its current price. For more information, visit the GF Value™ page.

What Does CSX's GF Score™ Tell Us? The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been found to generate higher long-term returns based on backtesting from 2006 to 2021.

Metric Rating GF Score™ 86/100 Financial Strength 4/10 Profitability 9/10 Growth 8/10 Valuation 5/10 Momentum 10/10 CSX has a predictability rank of 1/5 stars, indicating that the DCF model may be less reliable for this stock. For more information, visit the CSX stock page.

Key Assumptions and Limitations It is essential to recognize that DCF models are highly sensitive to the assumptions made regarding growth rates and discount rates. Stocks with low predictability ratings, such as CSX, tend to produce less reliable DCF estimates. The terminal growth rate of 4% used in this analysis is a simplifying assumption that may not reflect actual future performance.

What This Means for Investors In summary, the three valuation models—DCF earnings, DCF FCF, and GF Value™—all suggest that CSX is currently overvalued. This conclusion is supported by the significant margins of safety observed in both DCF models.

For the full DCF analysis, visit the CSX DCF Calculator. You can also explore the GF Value™ page, or use the GuruFocus Stock Screener to find undervalued predictable companies.

Frequently Asked Questions What is CSX's intrinsic value based on DCF?

[Answer: earnings-based $30.68, FCF-based $26.64]

Is CSX overvalued or undervalued?

[Answer using DCF + GF Value™ consensus]

How reliable is the DCF model for CSX?

[Answer using predictability rank 1/5]

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Key Takeaways DELL fits the screen with 47.4% fiscal 2026 revenue growth and 26.4% long-term EPS growth.HPE targets 31.3% fiscal 2026 revenue growth, with a 32% long-term earnings growth rate.These stocks combine dividend growth histories with revenue and earnings growth potential. Wall Street rallied comfortably on June 15, 2026, with major indices like the Dow Jones Industrial Average hitting a record high, as global oil prices tumbled to a three-month low amid fresh hopes that a U.S.-Iran peace deal could end the ongoing energy supply crisis. 

However, the long-term viability of this investor optimism remains shrouded in uncertainty, considering Israel’s latest announcement to keep its defense force in Lebanon indefinitely. 

Against this backdrop, risk-averse investors may find that steady dividend-growth stocks offer a more balanced mix of income and stability than high-beta growth plays at this stage.

These dividend-growth stocks boast a consistent track record of raising payouts, underscoring the balance-sheet strength and cash-flow resilience required to navigate a period in which the traditional growth narrative is being reassessed.

Stocks with a strong history of year-over-year dividend growth can help build a resilient portfolio with greater potential for capital appreciation compared to simple dividend-paying or high-yield stocks. 

We have selected three dividend growth stocks — Dell Technologies (DELL - Free Report) , Hewlett Packard (HPE - Free Report) and Taiwan Semiconductor (TSM - Free Report) — that could be solid choices for your portfolio.

Why Is Dividend Growth Better?Stocks with a strong history of dividend growth are typically associated with mature companies that are less prone to sharp market swings, allowing them to serve as a hedge against economic or political uncertainty, as well as broader market volatility. Their steadily rising payouts provide a measure of downside protection.

These companies are generally backed by solid fundamentals, making them attractive long-term dividend-growth investments. Key strengths include durable business models, consistent profitability, expanding cash flows, healthy liquidity, strong balance sheets and attractive valuations.

A consistent history of dividend growth underscores the potential for continued growth ahead.

Although these stocks do not necessarily have the highest yields, they have outperformed the broader stock market or any other dividend-paying stock for an extended period.

As a result, selecting dividend-growth stocks appears to be a winning strategy when other key parameters are taken into account.

5-Year Historical Dividend Growth Greater Than Zero: This selects stocks with a solid dividend growth history.

5-Year Historical Sales Growth Greater Than Zero: This represents stocks with a strong record of growing revenues.

5-Year Historical EPS Growth Greater Than Zero: This represents stocks with a solid earnings growth history.

Next 3-5 Year EPS Growth Rate Greater Than Zero: This represents the rate at which a company’s earnings are expected to grow. Improving earnings should help companies sustain dividend payments.

Price/Cash Flow Less Than M-Industry: A ratio lower than the industry median indicates that a stock is undervalued within its industry, meaning an investor would pay less for the company’s cash flow.

52-Week Price Change Greater Than S&P 500 (Market Weight): This ensures that a stock has appreciated more than the S&P 500 over the past year.

Top Zacks Rank: Stocks having a Zacks Rank #1 (Strong Buy) and 2 (Buy) generally outperform their peers in all types of market environments.

Growth Score of B or better: Our research shows that stocks with a Growth Score of A or B, when combined with a Zacks Rank #1 or 2, offer the best upside potential.

These few criteria alone narrowed the universe from more than 7,700 stocks to just three.

Here are the three stocks that fit the bill:

Texas-based Dell Technologies is a leading provider of servers, storage, and persona computers. The company’s IT solutions support customers in traditional infrastructure and multi-cloud environments. The Zacks Consensus Estimate for DELL’s fiscal 2026 revenues suggests a year-over-year improvement of 47.4%. The stock boasts a long-term (three-to-five years) earnings growth rate of 26.40%. It has an annual dividend yield of 0.64%.

DELL currently sports a Zacks Rank #1 and has a Growth Score of A. You can see the complete list of today’s Zacks #1 Rank stocks here.

Headquartered in Texas, Hewlett Packard is an enterprise-facing hardware and service business that focuses on servers, supercomputers, storage, networking and cloud services. The Zacks Consensus Estimate for HPE’s fiscal 2026 revenues suggests a year-over-year improvement of 31.3%. The stock boasts a long-term earnings growth rate of 32% and has an annual dividend yield of 1.18%.

HPE currently sports a Zacks Rank #1 and a Growth Score of B.

Taiwan-based Taiwan Semiconductor is the world's first dedicated semiconductor foundry. It manufactures integrated circuits for its customers based on their proprietary IC designs using its advanced production processes. The Zacks Consensus Estimate for TSM’s  2026 revenues suggests a year-over-year improvement of 32.2%. The stock boasts a long-term earnings growth rate of 22.4% and has an annual dividend yield of 0.71%.

TSM currently holds a Zacks Rank #2 and a Growth Score of A.  

Dell Technologies (NYSE: DELL) announces that its board of directors has declared a quarterly cash dividend of $0.63 per common share, which will be payable on July 31 to shareholders of record as of July 21.

About Dell Technologies

Dell Technologies NYSE:DELL helps organizations and individuals build their digital future and transform how they work, live and play. The company provides customers with the industry’s broadest and most innovative technology and services portfolio for the AI era.

Copyright © 2026 Dell Inc. or its subsidiaries. All Rights Reserved. Dell Technologies, Dell, EMC and Dell EMC are trademarks of Dell Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260616188737/en/

The logo of EssilorLuxottica is seen during the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France, June 12, 2025.... Purchase Licensing Rights, opens new tab Read more

CompaniesJune 16 (Reuters) - EssilorLuxottica (ESLX.PA), opens new tab, the world's largest ​eyewear maker, has signed a long-term ‌deal with chipmaking equipment company Applied Materials (AMAT.O), opens new tab to develop augmented reality display technology and AI ​glasses, the companies said on Tuesday.

Here ​are some details:

Get a daily digest of breaking business news straight to your inbox with the Reuters Business newsletter. Sign up here.

EssilorLuxottica and Applied Materials will ⁠scale up commercialisation of AI glasses

Research ​and development will focus on advanced optical ​technologies

EssilorLuxottica already leads the AI-glasses market through a long-term partnership with Meta (META.O), opens new tab to sell smart glasses under ​the Ray-Ban and Oakley brands

Their first ​device with a built-in display, the Ray-Ban Meta Display, was ‌launched ⁠in 2025

AI-powered glasses embed a camera, microphone and speakers into a conventional frame, with an AI voice assistant that answers ​questions and ​describes surroundings

Augmented ⁠reality, which overlays digital images onto the user's field of ​vision, is a far more complex ​optical ⁠challenge

California-based Applied Materials makes the specialised equipment used to engineer the ultra-thin material ⁠layers ​at the heart of semiconductor ​chips needed for AR displays

Reporting by Gianluca Lo Nostro; ​Editing by Emelia Sithole-Matarise and Barbara Lewis

Our Standards: The Thomson Reuters Trust Principles., opens new tab

, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zoetis Inc. (NYSE: ZTS).

Shareholders who purchased shares of ZTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/zoetis-inc-loss-submission-form-2/?id=188276&from=4

CLASS PERIOD: January 14, 2025 to May 6, 2026

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (ii) Zoetis' Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (iii) Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment.

DEADLINE: July 27, 2026 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/zoetis-inc-loss-submission-form-2/?id=188276&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ZTS during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is July 27, 2026. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

SOURCE The Gross Law Firm

NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

The class action concerns whether Zoetis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

You have until July 27, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Zoetis securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.   

[Click here for information about joining the class action]  

On May 7, 2026, Zoetis reported financial results for the first quarter of 2026.  Among other items, Zoetis reported net income of $601 million, flat year over year, and cut its full year 2026 profit guidance to between $6.85 and $7 a share, down from prior guidance of $7.00 to $7.10 a share.  In the earnings release, CEO Kristin Peck said that “the first quarter unfolded in a more challenging operating environment than we anticipated. Pet owners demonstrated increased price sensitivity, resulting in a decline in veterinary visits and softer demand[.]” 

On this news, Zoetis’s stock price fell $23.91 per share, or 21.5%, to close at $87.31 per share on May 7, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT: 
Danielle Peyton 
Pomerantz LLP 
[email protected] 
646-581-9980 ext. 7980 

On June 16, 2026, we present a discounted cash flow (DCF) analysis for Elevance Health Inc ELV . The stock has shown a price performance of -3.5% over the past week, +2.8% over the past month, +15.8% year-to-date, and +6.7% over the past year.

DCF Earnings-based intrinsic value of $643.27 vs current price of $401.89 (margin of safety: 37.5%) DCF FCF-based intrinsic value of $396.80 vs current price (second opinion: fair valued with -1.3% margin of safety) GF Score™ of 90/100 indicating high reliability of the DCF inputs What Is ELV Worth? DCF Earnings-Based Model The DCF earnings-based model for Elevance Health Inc ELV utilizes a two-stage approach, where we first project earnings growth for the initial 10 years, followed by a terminal growth phase. The current EPS, excluding non-recurring items, is $30.78, and we anticipate a growth rate of 14.0% over the next decade. The discount rate applied is 11%, which combines a risk-free rate of 5% and an equity risk premium of 6%.

Parameter Value Current EPS (TTM, excl. non-recurring) $30.78 10-Year Growth Rate 14.0% 10-Year Treasury Rate 4.44% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% In the first stage, we expect EPS to grow at 14.0% annually for 10 years, resulting in a growth stage value of $357.47 per share. In the second stage, we apply a terminal growth rate of 4% for the next 10 years, yielding a terminal stage value of $285.80 per share. The intrinsic value is calculated by summing both stages:

Stage Description Value Growth Stage (Years 1-10) EPS growing at 14.0%, discounted at 11% $357.47 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $285.80 Intrinsic Value Growth + Terminal $643.27 With the current price at $401.89, the intrinsic value of $643.27 indicates that the stock is significantly undervalued, with a margin of safety of 37.5%. It is important to note that GuruFocus uses EPS without non-recurring items because research shows stock prices correlate more closely with earnings than free cash flow. For further details, visit the ELV DCF Calculator.

What Does the Free Cash Flow DCF Say? The free cash flow (FCF)-based intrinsic value for Elevance Health Inc is calculated at $396.80. When compared to the earnings-based intrinsic value of $643.27, the FCF model suggests a different perspective, indicating that the stock is fair valued with a margin of safety of -1.3%. This divergence highlights the importance of considering multiple valuation methods when assessing a stock's worth.

How Does GF Value™ Compare to the DCF Models? The GF Value™ for Elevance Health Inc is calculated at $508.90, providing a third perspective on valuation. GF Value™ is GuruFocus' proprietary measure derived from historical trading multiples, past business growth, and future performance estimates. In this case, while the DCF earnings model suggests significant undervaluation, the FCF model indicates fair valuation, and GF Value™ falls in between, suggesting that all three models present a nuanced view of ELV's valuation. For more information, visit the GF Value™ page.

What Does ELV's GF Score™ Tell Us? The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been found to generate higher long-term returns based on backtested data from 2006 to 2021.

Metric Rating GF Score™ 90/100 Financial Strength 5/10 Profitability 8/10 Growth 9/10 Valuation 8/10 Momentum 8/10 With a predictability rank of 2 out of 5 stars, it indicates that the DCF model may be less reliable for this stock. For more details, visit the ELV stock page.

Key Assumptions and Limitations It is essential to recognize that DCF models are highly sensitive to growth rate and discount rate assumptions. Stocks with low predictability ratings, such as Elevance Health Inc, produce less reliable DCF estimates. Additionally, the terminal growth rate of 4% is a simplifying assumption that may not reflect future market conditions accurately.

What This Means for Investors In synthesizing the three valuation models—DCF earnings, DCF FCF, and GF Value™—we find a mixed picture for Elevance Health Inc. The DCF earnings model suggests the stock is significantly undervalued, while the FCF model indicates it is fair valued. The GF Value™ falls in between these assessments. Overall, investors should consider the varying perspectives before making investment decisions. For the full DCF analysis, visit the ELV DCF Calculator. You can also explore the GF Value™ page, or use the GuruFocus Stock Screener to find undervalued predictable companies.

Frequently Asked Questions What is ELV's intrinsic value based on DCF?

According to our analysis, the earnings-based intrinsic value is $643.28, while the FCF-based intrinsic value is $396.80.

Is ELV overvalued or undervalued?

The DCF earnings model suggests that ELV is undervalued, while the FCF model indicates it is fair valued. The GF Value™ also provides a mixed perspective.

How reliable is the DCF model for ELV?

With a predictability rank of 2 out of 5 stars, the DCF model's reliability for ELV is considered lower.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

© Stockcrafterpro / Shutterstock.com

Western Digital (NASDAQ:WDC | WDC Price Prediction) stock is up 7% in Tuesday morning trading, changing hands near $701 and setting a fresh all-time high. The catalyst is a Morgan Stanley note that reiterated an Overweight rating and lifted its WDC price target by 33%.

The upgrade extends a powerful run. Western Digital stock closed Monday up 16.1% at $653.53, a third straight up day with a Monday intraday high of $658.80.

Seagate Technology (NASDAQ:STX) stock is participating, up 5% to around $1,072 in the early Tuesday hours. SanDisk (NASDAQ:SNDK) and Micron Technology (NASDAQ:MU) shares are also rising modestly, each up 1% as the AI storage trade broadens across the complex.

Morgan Stanley’s 33% Price-Target Hike Lights the Fuse Morgan Stanley raised its Western Digital stock price target to $650 from $488, framing the company’s dual-tracked UltraSMR and HAMR roadmap as undervalued by investors. The bank described HAMR as a source of reliability and strength rather than a technology gap versus peers.

The firm also lifted its per-share earnings estimates for Western Digital to $22.40 for next year and $43.47 for 2028. Morgan Stanley argued Western Digital stock could double next year if its bull-case pricing assumptions play out.

The note lands on top of unusually strong fundamentals. Western Digital reported Q3 FY2026 revenue of $3.34 billion, up 46% year over year (YoY), with non-GAAP gross margin crossing 50% for the first time. Moreover, Western Digital’s management raised the company’s dividend by 20% to $0.15 per share.

Seagate Gains 5% as the AI Storage Trade Broadens Seagate stock is riding the same tailwind. Morgan Stanley separately raised its STX price target to $1,035 from $767 on June 15, while Mizuho and Citi pushed their targets to $1,090 and $1,150, respectively.

The fundamentals back the optimism. Seagate posted Q3 FY2026 non-GAAP revenue of $3.11 billion, up 44% YoY, with free cash flow of $953 million and the data center segment accounting for 80% of total revenue.

CEO Dave Mosley asserted that “Seagate is entering a new era of structural growth as AI applications amplify data creation.” HAMR-based Mozaic drives sit at the center of that thesis, and the analyst community is leaning in.

Super-cycle or Bubble? The Debate Heats Up The community is split. The bulls point to a memory and storage super-cycle in motion: SanDisk’s datacenter segment jumped 645% YoY to $1.47 billion last quarter, and Micron just guided Q3 revenue to $33.5 billion with non-GAAP gross margin near 81%.

The bears counter that valuations have re-rated very quickly. Western Digital stock now trades at a P/E ratio of 39x with a 50-day moving average of $456.29, and the company’s prediction-markets dashboard flags insider net direction as selling. Seagate insiders have also trimmed their positions in recent weeks.

Wall Street still skews bullish. Western Digital stock carries 21 Buy ratings against 3 Holds and 1 Sell, and Seagate stock shows a similar split with an analyst consensus target of $885.91. Reddit chatter on the storage complex registered a very bullish sentiment score of 88 on Monday.

What to Watch Investors can watch for whether Western Digital stock holds above $700. Follow-on analyst notes and any Computex 2026 commentary could keep momentum traders active through the afternoon.

Micron’s upcoming earnings print is the next major data point on the calendar. A confirming beat could reinforce the super-cycle narrative, while any guide-down may give bears the opening they’ve been looking for across WDC, STX, and other memory/storage stocks like Micron Technology (NASDAQ:MU) and SanDisk (NASDAQ:SNDK).